Secondary stroke prevention among stroke survivors in Riyadh city, Saudi Arabia

References

1. ↵
   1. Radak D,
   2. Katsiki N,
   3. Resanovic I,
   4. Jovanovic A,
   5. Sudar-Milovanovic E,
   6. Zafirovic S,
   7. et al.

   (2017) Apoptosis and Acute Brain Ischemia in Ischemic Stroke. Curr Vasc Pharmacol 15, 115–122.
2. ↵
   1. Writing Group Members,
   2. Mozaffarian D,
   3. Benjamin EJ,
   4. Go AS,
   5. Arnett DK,
   6. Blaha MJ,
   7. et al.

   (2016) Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 133, e38–e360.
3. ↵
   1. GBD Stroke Collaborators

   (2019) Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18, 439–458.
4. ↵
   1. Gorelick PB

   (2019) The global burden of stroke: persistent and disabling. Lancet Neurol 18, 417–418.
5. ↵
   1. Almekhlafi MA

   (2016) Trends in one-year mortality for stroke in a tertiary academic center in Saudi Arabia: a 5-year retrospective analysis. Ann Saudi Med 36, 197–202.
6. ↵
   1. Alanazy MH,
   2. Barakeh RB,
   3. Asiri A,
   4. Edrees MF,
   5. Abuzinadah AR,
   6. Aljafen BN,
   7. et al.

   (2018) Practice Patterns and Barriers for Intravenous Thrombolysis: A Survey of Neurologists in Saudi Arabia. Neurol Res Int 2018, 1695014.
7. ↵
   1. Al-Senani F,
   2. Al-Johani M,
   3. Salawati M,
   4. ElSheikh S,
   5. AlQahtani M,
   6. Muthana J,
   7. et al.

   (2019) A national economic and clinical model for ischemic stroke care development in Saudi Arabia: A call for change. Int J Stroke 14, 835–842.
8. ↵
   1. Zheng S,
   2. Yao B

   (2019) Impact of risk factors for recurrence after the first ischemic stroke in adults: A systematic review and meta-analysis. J Clin Neurosci 60, 24–30.
9. ↵
   1. Mohan KM,
   2. Wolfe CDA,
   3. Rudd AG,
   4. Heuschmann PU,
   5. Kolominsky-Rabas PL,
   6. Grieve AP

   (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42, 1489–1494.
10. ↵
    1. Krishnan S,
    2. Pappadis MR,
    3. Weller SC,
    4. Stearnes M,
    5. Kumar A,
    6. Ottenbacher KJ,
    7. et al.

    (2017) Needs of Stroke Survivors as Perceived by Their Caregivers: A Scoping Review. Am J Phys Med Rehabil 96, 487–505.
11. ↵
    1. Spence JD

    (2017) Recent advances in preventing stroke recurrence. F1000Res 6, 1017.
12. ↵
    1. Hackam DG,
    2. Spence JD

    (2007) Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 38, 1881–1885.
13. ↵
    1. Lehane E,
    2. McCarthy G

    (2009) Medication non-adherence-exploring the conceptual mire. Int J Nurs Pract 15, 25–31.
14. ↵
    1. Chapman B,
    2. Bogle V

    (2014) Adherence to medication and self-management in stroke patients. Br J Nurs 23, 158–166.
15. ↵
    1. Peter J,
    2. Justus AH

    (2016) Knowledge and Practices of Stroke Survivors Regarding Secondary Stroke Prevention, Khomas Region, Namibia. Journal of Medical Biomedical and Applied Sciences 3.
16. ↵
    1. Sappok T,
    2. Faulstich A,
    3. Stuckert E,
    4. Kruck H,
    5. Marx P,
    6. Koennecke HC

    (2001) Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 32, 1884–1889.
17. ↵
    1. Sidorkiewicz S,
    2. Tran VT,
    3. Cousyn C,
    4. Perrodeau E,
    5. Ravaud P

    (2016) Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open 6, e010510.
18. ↵
    1. Coull AJ,
    2. Lovett JK,
    3. Rothwell PM,
    4. Oxford Vascular S

    (2004) Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328, 326.
19. ↵
    1. Clark TG,
    2. Murphy MFG,
    3. Rothwell PM

    (2003) Long term risks of stroke, myocardial infarction, and vascular death in “low risk” patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 74, 577–580.
20. ↵
    1. van Wijk I,
    2. Kappelle LJ,
    3. van Gijn J,
    4. Koudstaal PJ,
    5. Franke CL,
    6. Vermeulen M,
    7. et al.

    (2005) Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 365, 2098–2104.
21. ↵
    1. Edwards JD,
    2. Kapral MK,
    3. Fang J,
    4. Swartz RH

    (2017) Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack. CMAJ 189, E954–E61.
22. ↵
    1. Hardie K,
    2. Hankey GJ,
    3. Jamrozik K,
    4. Broadhurst RJ,
    5. Anderson C

    (2004) Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 35, 731–735.
23. ↵
    1. Wellwood I,
    2. Dennis MS,
    3. Warlow CP

    (1994) Perceptions and knowledge of stroke among surviving patients with stroke and their carers. Age Ageing 23, 293–298.
24. ↵
    1. Ellis C,
    2. Barley J,
    3. Grubaugh A

    (2013) Poststroke knowledge and symptom awareness: a global issue for secondary stroke prevention. Cerebrovasc Dis 35, 572–581.
25. ↵
    1. Saengsuwan J,
    2. Suangpho P,
    3. Tiamkao S

    (2017) Knowledge of Stroke Risk Factors and Warning Signs in Patients with Recurrent Stroke or Recurrent Transient Ischaemic Attack in Thailand. Neurol Res Int 2017, 8215726.
26. ↵
    1. Sjölander M,
    2. Eriksson M,
    3. Glader EL

    (2013) The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open 3, e003551.
27. ↵
    1. Cheiloudaki E,
    2. Alexopoulos EC

    (2019) Adherence to Treatment in Stroke Patients. Int J Environ Res Public Health 16, 196.
28. ↵
    1. Kaddumukasa M,
    2. Kayima J,
    3. Kaddumukasa MN,
    4. Ddumba E,
    5. Mugenyi L,
    6. Pundik S,
    7. et al.

    (2015) Knowledge, attitudes and perceptions of stroke: a cross-sectional survey in rural and urban Uganda. BMC Res Notes 8, 819.
29. ↵
    1. Basfar W,
    2. Al-Sebyani A,
    3. Aljawi G,
    4. Milyani H,
    5. Jan M

    (2016) Public Knowledge of Stroke Amongst a Saudi Population. World Journal of Research and Review 3, 10–12.
30. ↵
    1. Aljefree N,
    2. Ahmed F

    (2015) Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: a systematic review. Advances in Public Health 2015.
31. ↵
    1. Luger S,
    2. Hohmann C,
    3. Niemann D,
    4. Kraft P,
    5. Gunreben I,
    6. Neumann-Haefelin T,
    7. et al.

    (2015) Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants. Patient Prefer Adherence 9, 1695–705.
32. ↵
    1. Tulek Z,
    2. Dünya C,
    3. Çiftçioğlu R,
    4. Dereci H

    (2019) Determination of Factors that Impact Adherence to Warfarin in Patients with Stroke. Turkish Journal Of Neurology 25, 146–152.
33. ↵
    1. Zhang H,
    2. Qian HZ,
    3. Meng SQ,
    4. Shu M,
    5. Gao YZ,
    6. Xu Y,
    7. et al.

    (2015) Psychological distress, social support and medication adherence in patients with ischemic stroke in the mainland of China. J Huazhong Univ Sci Technolog Med Sci 35, 405–410.
34. ↵
    1. Vincent-Onabajo G,
    2. Moses T

    (2016) Knowledge of Stroke Risk Factors among Stroke Survivors in Nigeria. Stroke Res Treat 2016, 1902151.
35. ↵
    1. Sundseth A,
    2. Faiz KW,
    3. Rønning OM,
    4. Thommessen B

    (2014) Factors related to knowledge of stroke symptoms and risk factors in a norwegian stroke population. J Stroke Cerebrovasc Dis 23, 1849–1855.
36. ↵
    1. Zeng Y,
    2. He GP,
    3. Yi GH,
    4. Huang YJ,
    5. Zhang QH,
    6. He LL

    (2012) Knowledge of stroke warning signs and risk factors among patients with previous stroke or TIA in China. J Clin Nurs 21, 2886–2895.
37. ↵
    1. Senior V,
    2. Marteau TM,
    3. Weinman J,
    4. Genetic Risk Assessment for FHTSG

    (2004) Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions. Cardiovasc Drugs Ther 18, 475–481.
38. ↵
    1. Jin J,
    2. Sklar GE,
    3. Min Sen Oh V,
    4. Chuen Li S

    (2008) Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag 4, 269–286.
39. ↵
    1. O’Carroll R,
    2. Whittaker J,
    3. Hamilton B,
    4. Johnston M,
    5. Sudlow C,
    6. Dennis M

    (2011) Predictors of adherence to secondary preventive medication in stroke patients. Ann Behav Med 41, 383–390.
40. ↵
    1. Glader EL,
    2. Sjölander M,
    3. Eriksson M,
    4. Lundberg M

    (2010) Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41, 397–401.
41. ↵
    1. Jamison J,
    2. Sutton S,
    3. Mant J,
    4. De Simoni A

    (2017) Barriers and facilitators to adherence to secondary stroke prevention medications after stroke: analysis of survivors and caregivers views from an online stroke forum. BMJ Open 7, e016814.
42. ↵
    1. Chambers JA,
    2. O’Carroll RE,
    3. Hamilton B,
    4. Whittaker J,
    5. Johnston M,
    6. Sudlow C,
    7. et al.

    (2011) Adherence to medication in stroke survivors: a qualitative comparison of low and high adherers. Br J Health Psychol 16, 592–609.
43. ↵
    1. Al AlShaikh S,
    2. Quinn T,
    3. Dunn W,
    4. Walters M,
    5. Dawson J

    (2016) Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: A systematic review and meta-analyses. Eur Stroke J 1, 65–75.
44. ↵
    1. Lummis HL,
    2. Sketris IS,
    3. Gubitz GJ,
    4. Joffres MR,
    5. Flowerdew GJ

    (2008) Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol 8, 25.
45. ↵
    1. Østergaard K,
    2. Madsen C,
    3. Liu ML,
    4. Bak S,
    5. Hallas J,
    6. Gaist D

    (2014) Long-term use of antiplatelet drugs by patients with transient ischaemic attack. Eur J Clin Pharmacol 70, 241–248.
46. ↵
    1. Ovbiagele B,
    2. Saver JL,
    3. Fredieu A,
    4. Suzuki S,
    5. Selco S,
    6. Rajajee V,
    7. et al.

    (2004) In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke 35, 2879–83.